Press Release

NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced today the closing of its previously …

[Read more...] about Celsus Therapeutics Announces the Closing of $9.2 Million Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs

NEW YORK AND LONDON Celsus Therapeutics Plc (NASDAQ:CLTX)(formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the …

[Read more...] about Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ

NEW YORK AND LONDON Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage biopharmaceutical company, announces the appointment of Pablo …

[Read more...] about Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer

NEW YORK AND LONDON Celsus Therapeutics(OTCQB: CLSXY), an emerging growth, development-stage biopharmaceutical company, announced today the addition of …

[Read more...] about Celsus Therapeutics Names Allan Shaw to Board of Directors

NEW YORK AND LONDON Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage biopharmaceutical company, announced that the Company MRX-6 …

[Read more...] about Celsus Therapeutics MRX-6 Selected as One of the “Top Autoimmune/Anti-Inflammatory Disease Projects to Watch” by Elsevier Business Intelligence